[Therapeutic drug monitoring in child and adolescent psychiatry--practical recommendations]. 2006

Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie der Universität Würzburg. manfred.gerlach@mail.uni-wuerzburg.de

The therapy of children and adolescents with psychotropic drugs differs from that of adults. Due to the differences in the pharmacokinetic behaviour of the drugs used that are dependent on a child's, respectively an adolescent's stage of development, the same dosages as recommended for adults cannot be used. Moreover, many of the drugs used have not been approved for use in children and adolescents. Thus the criteria which guarantee their efficacy and safety for use in adults do not apply for their use in children and adolescents. Therefore therapeutic drug monitoring (TDM) is a general indication for the administration of psychotropic drugs in children and adolescents. TDM enables the clinician to adjust the dosage of a drug according to the characteristics of the individual patient. It is also a valid tool to increase the safety of therapy and optimise therapy with psychotropic drugs. However, standardized studies are also needed to find therapeutic ranges of plasma concentrations for children and adolescents. Such studies will deliver new insights into the pharmacokinetic and pharmacodynamic behaviour of drugs used in child and adolescent psychiatry. The present contribution begins with a brief description of the strategy of TDM in psychiatry, followed by a discussion of the characteristics of pharmacotherapy in child and adolescent psychiatry and the reasons for the general indication of TDM in children and adolescents. Finally, recommendations are given for the routine performance of TDM. For a detailed treatment of TDM in psychiatry, the interested reader is referred to the AG-NP-TDM Expert Group Consensus Guidelines published earlier (Baumann et al., 2004).

UI MeSH Term Description Entries
D008658 Inactivation, Metabolic Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion. Detoxication, Drug, Metabolic,Drug Detoxication, Metabolic,Metabolic Detoxication, Drug,Detoxification, Drug, Metabolic,Metabolic Detoxification, Drug,Metabolic Drug Inactivation,Detoxication, Drug Metabolic,Detoxication, Metabolic Drug,Detoxification, Drug Metabolic,Drug Inactivation, Metabolic,Drug Metabolic Detoxication,Drug Metabolic Detoxification,Inactivation, Metabolic Drug,Metabolic Drug Detoxication,Metabolic Inactivation
D011619 Psychotropic Drugs A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). Psychoactive Agent,Psychoactive Agents,Psychoactive Drug,Psychopharmaceutical,Psychopharmaceuticals,Psychotropic Drug,Psychoactive Drugs,Agent, Psychoactive,Agents, Psychoactive,Drug, Psychoactive,Drug, Psychotropic,Drugs, Psychoactive,Drugs, Psychotropic
D011785 Quality Assurance, Health Care Activities and programs intended to assure or improve the quality of care in either a defined medical setting or a program. The concept includes the assessment or evaluation of the quality of care; identification of problems or shortcomings in the delivery of care; designing activities to overcome these deficiencies; and follow-up monitoring to ensure effectiveness of corrective steps. Quality Assessment, Health Care,Health Care Quality Assessment,Health Care Quality Assurance,Healthcare Quality Assessment,Healthcare Quality Assurance,Quality Assessment, Healthcare,Quality Assurance, Healthcare,Assessment, Healthcare Quality,Assessments, Healthcare Quality,Assurance, Healthcare Quality,Assurances, Healthcare Quality,Healthcare Quality Assessments,Healthcare Quality Assurances,Quality Assessments, Healthcare,Quality Assurances, Healthcare
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D001523 Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function. Mental Illness,Psychiatric Diseases,Psychiatric Disorders,Psychiatric Illness,Behavior Disorders,Diagnosis, Psychiatric,Mental Disorders, Severe,Psychiatric Diagnosis,Illness, Mental,Mental Disorder,Mental Disorder, Severe,Mental Illnesses,Psychiatric Disease,Psychiatric Disorder,Psychiatric Illnesses,Severe Mental Disorder,Severe Mental Disorders

Related Publications

Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
September 2011, Pharmacopsychiatry,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
July 2005, Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
November 2016, Expert opinion on drug safety,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
May 2006, Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
November 2017, Clinical pharmacology and therapeutics,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
September 2011, Pharmacopsychiatry,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
September 2011, Pharmacopsychiatry,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
January 2023, Casopis lekaru ceskych,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
June 2006, Journal of child and adolescent psychopharmacology,
Manfred Gerlach, and Silke Rothenhöfer, and Claudia Mehler-Wex, and Joerg M Fegert, and Eberhard Schulz, and Christoph Wewetzer, and Andreas Warnke
April 1979, Acta paedopsychiatrica,
Copied contents to your clipboard!